Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease ; volume:12 ; number:1 ; day:28 ; month:6 ; year:2024 ; pages:1-4 ; date:12.2024
Acta Neuropathologica Communications ; 12, Heft 1 (28.6.2024), 1-4, 12.2024
- Urheber
-
Henderson, Michael X.
Sengupta, Medha
Trojanowski, John Q.
Lee, Virginia M. Y.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-024-01819-7
- URN
-
urn:nbn:de:101:1-2410080927235.638132601369
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Henderson, Michael X.
- Sengupta, Medha
- Trojanowski, John Q.
- Lee, Virginia M. Y.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
Crystallizing the Parkinson’s disease protein LRRK2 under microgravity conditions
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
Crystallizing the Parkinson’s disease protein LRRK2 under microgravity conditions
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?